Is the customer always right

摘要

The synthetic methods used by the medicinal chemist are typically designed for diversity and as such) are only rarely capable, at least without further development, of meeting the initial aim of any programme to provide material for development studies. It is even rarer that these methods provide the optimum synthetic route for commercialisation purposes. Yet both large and small R&D organisations often ignore this issue during the early development phases and simply scale-up the Medicinal chemistry methods. In this article we will explore why this is and why this mind-set should change if a company is to reduce costs in development and provide opportunities for more cost effective products for payers.